Literature DB >> 26376447

Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke.

Krishnaj Gourab1, Brian D Schmit2, T George Hornby3.   

Abstract

OBJECTIVE: To investigate the effects of single doses of a selective serotonin reuptake inhibitor (SSRI) on lower limb voluntary and reflex function in individuals with chronic stroke.
DESIGN: Double-blind, randomized, placebo-controlled crossover trial.
SETTING: Outpatient research setting. PARTICIPANTS: Individuals (N=10; 7 men; mean age ± SD, 57±10y) with poststroke hemiplegia of >1 year duration who completed all assessments.
INTERVENTIONS: Patients were assessed before and 5 hours after single-dose, overencapsulated 10-mg doses of escitalopram (SSRI) or placebo, with 1 week between conditions. MAIN OUTCOME MEASURES: Primary assessments included maximal ankle and knee isometric strength, and velocity-dependent (30°/s-120°/s) plantarflexor stretch reflexes under passive conditions, and separately during and after 3 superimposed maximal volitional drive to simulate conditions of increased serotonin release. Secondary measures included clinical measures of lower limb coordination and locomotion.
RESULTS: SSRI administration significantly increased stretch reflex torques at higher stretch velocities (eg, 90°/s; P=.03), with reflexes at lower velocities enhanced by superimposed voluntary drive (P=.02). No significant improvements were seen in volitional peak torques or in clinical measures of lower limb function (lowest P=.10).
CONCLUSIONS: Increases in spasticity but not strength or lower limb function were observed with single-dose SSRI administration in individuals with chronic stroke. Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, is required to elicit significant benefit of these agents on lower limb function poststroke.
Copyright © 2015 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Muscle spasticity; Muscle strength; Rehabilitation; Serotonin; Stroke

Mesh:

Substances:

Year:  2015        PMID: 26376447     DOI: 10.1016/j.apmr.2015.08.431

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

1.  The serotonin reuptake blocker citalopram destabilizes fictive locomotor activity in salamander axial circuits through 5-HT1A receptors.

Authors:  Aurélie Flaive; Jean-Marie Cabelguen; Dimitri Ryczko
Journal:  J Neurophysiol       Date:  2020-05-13       Impact factor: 2.714

Review 2.  Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

Authors:  Lynn A Legg; Ann-Sofie Rudberg; Xing Hua; Simiao Wu; Maree L Hackett; Russel Tilney; Linnea Lindgren; Mansur A Kutlubaev; Cheng-Fang Hsieh; Amanda J Barugh; Graeme J Hankey; Erik Lundström; Martin Dennis; Gillian E Mead
Journal:  Cochrane Database Syst Rev       Date:  2021-11-15

Review 3.  Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke.

Authors:  Janne Kaergaard Mortensen; Grethe Andersen
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

4.  Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

Authors:  Lynn A Legg; Russel Tilney; Cheng-Fang Hsieh; Simiao Wu; Erik Lundström; Ann-Sofie Rudberg; Mansur A Kutlubaev; Martin Dennis; Babak Soleimani; Amanda Barugh; Maree L Hackett; Graeme J Hankey; Gillian E Mead
Journal:  Cochrane Database Syst Rev       Date:  2019-11-26

Review 5.  Spasticity, Motor Recovery, and Neural Plasticity after Stroke.

Authors:  Sheng Li
Journal:  Front Neurol       Date:  2017-04-03       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.